A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs RG 7880 (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Genentech
- 01 Feb 2019 Planned End Date changed from 6 Jul 2022 to 17 Dec 2022.
- 01 Feb 2019 Planned primary completion date changed from 6 Jul 2022 to 17 Dec 2022.
- 04 Jan 2019 Status changed from not yet recruiting to recruiting.